---
title: "QYUNS: Reached a global exclusive licensing agreement with Roche for QX031N, receiving a $75 million upfront payment"
description: "QYUNS announced that the company has reached a global exclusive collaboration and licensing agreement with Roche. According to the agreement, the company grants Roche global exclusive rights to develo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263050947.md"
published_at: "2025-10-28T09:52:31.000Z"
---

# QYUNS: Reached a global exclusive licensing agreement with Roche for QX031N, receiving a $75 million upfront payment

> QYUNS announced that the company has reached a global exclusive collaboration and licensing agreement with Roche. According to the agreement, the company grants Roche global exclusive rights to develop, manufacture, and commercialize QX031N. The company expects to receive a one-time, non-refundable, and non-deductible upfront payment of $75 million, and is eligible to receive up to $995 million in milestone payments related to product development, regulatory approval, and commercialization, as well as tiered royalties on potential future product sales

QYUNS announced that the company has reached a global exclusive collaboration and licensing agreement with Roche. According to the agreement, the company grants Roche global exclusive rights to develop, manufacture, and commercialize QX031N. The company expects to receive a one-time, non-refundable, and non-deductible upfront payment of $75 million, and is eligible to receive up to $995 million in milestone payments related to product development, regulatory approval, and commercialization, as well as tiered royalties on potential future product sales

### Related Stocks

- [02509.HK - QYUNS-B](https://longbridge.com/en/quote/02509.HK.md)
- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued | Qyuns Therapeutics Co., Ltd. has initiated a share buyback program after the board determined that the stock is underval | [Link](https://longbridge.com/en/news/274983583.md) |
| Rovi jumps after announcing drug deal with Roche | Shares in Rovi rose about 8% following the announcement of a drug manufacturing deal with Roche. The agreement is expect | [Link](https://longbridge.com/en/news/262092937.md) |
| Obesity challenger Roche 'only scratching surface' of market potential, says CEO | Roche's CEO, Thomas Schinecker, expressed confidence in the growth potential of the weight-loss drug market, stating the | [Link](https://longbridge.com/en/news/262356985.md) |
| Roche shares rise as company advances experimental obesity drug to late-stage trial | Roche Holding's shares rose approximately 2% as the company advanced its experimental obesity drug CT-388 to late-stage  | [Link](https://longbridge.com/en/news/258317465.md) |
| Roche raises guidance on forecast-beating nine-month sales | FRANKFURT, Oct 23 (Reuters) - Swiss drugmaker Roche (ROG.S) on Thursday lifted its full-year guidance after reporting ni | [Link](https://longbridge.com/en/news/262348155.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.